Vadim Koshkin, MD
@vadimkoshkin.bsky.social
Associate Professor of Clinical Medicine @UCSF @ucsfcancer focusing on GU Oncology. Alum of @ClevelandClinic @umichmedicine @UChiPritzker Post re GU oncology
Reposted by Vadim Koshkin, MD
About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social
February 23, 2025 at 7:12 PM
About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social
Reposted by Vadim Koshkin, MD
Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...
February 15, 2025 at 3:36 PM
Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...
First post on this platform highlighting an important article.
Pembro rechallenge for mUC pts published in @euplatinum.bsky.social
Pts with response on Pembro stop Rx👉PD👉resume Pembro
Rechallenge works: ORR: 41% mOS: 26 mos
👇
Pembrolizumab Retreatment in mUC www.sciencedirect.com/science/arti...
Pembro rechallenge for mUC pts published in @euplatinum.bsky.social
Pts with response on Pembro stop Rx👉PD👉resume Pembro
Rechallenge works: ORR: 41% mOS: 26 mos
👇
Pembrolizumab Retreatment in mUC www.sciencedirect.com/science/arti...
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy
Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreat…
www.sciencedirect.com
February 4, 2025 at 4:17 AM
First post on this platform highlighting an important article.
Pembro rechallenge for mUC pts published in @euplatinum.bsky.social
Pts with response on Pembro stop Rx👉PD👉resume Pembro
Rechallenge works: ORR: 41% mOS: 26 mos
👇
Pembrolizumab Retreatment in mUC www.sciencedirect.com/science/arti...
Pembro rechallenge for mUC pts published in @euplatinum.bsky.social
Pts with response on Pembro stop Rx👉PD👉resume Pembro
Rechallenge works: ORR: 41% mOS: 26 mos
👇
Pembrolizumab Retreatment in mUC www.sciencedirect.com/science/arti...